INmune Bio Advances CORDStrom Toward Rare Disease Commercialization

Inmune Bio ( (INMB) ) has provided an announcement.

On February 10, 2026, INmune Bio submitted a pre-submission package to the U.K. Medicines and Healthcare Products Regulatory Agency for CORDStrom, a potential first systemic therapy for recessive dystrophic epidermolysis bullosa, following encouraging safety and efficacy data from its MissionEB trial and successful commercial-scale manufacturing runs in Stevenage. The company, which holds U.S. Orphan Drug and Rare Pediatric Disease designations for CORDStrom, also highlighted that recent U.S. legislation extending the FDA’s Rare Pediatric Disease Priority Review Voucher program to 2029 could enhance the economic and regulatory incentives around eventual approval, as it prepares for a U.S. biologics license application and broader regulatory filings later in 2026.

On February 12, 2026, INmune Bio reported it had received official minutes from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, marking another regulatory milestone in the CORDStrom development pathway. Together, the U.K. pre-submission and the U.S. regulatory interactions underscore the company’s transition from clinical development toward potential commercialization in a high-need rare disease market, with implications for patients, investors, and the broader rare pediatric disease therapeutics landscape.

The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Score is held back primarily by weak financial performance (large losses and sustained cash burn). The latest earnings call provides a meaningful offset via improved quarterly loss profile, stated cash runway into late 2026, and defined regulatory milestones, while technicals are mixed and valuation is constrained by negative earnings and no dividend.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Its three product platforms are CORDStrom, an allogeneic human umbilical cord-derived mesenchymal stromal cell therapy platform; XPro, a DN-TNF biologic targeting inflammatory pathways; and INKmune, a cell-based therapy designed to enhance natural killer cell activity in cancer.

Average Trading Volume: 401,599

Technical Sentiment Signal: Sell

Current Market Cap: $41.74M

For an in-depth examination of INMB stock, go to TipRanks’ Overview page.